Related Experiment Video
Updated: May 16, 2026

Lipidomics and Transcriptomics in Neurological Diseases
Published on: March 18, 2022
Human serum amyloid A (SAA) protein changes in acute epilepsy patients
Guifen Li1, Fang Ren, Jinhua Yao
1The First Affiliated Hospital of Xinxiang Medical University, Weihui, Henan Province, China. epilepsy doctor@163.com
Abstract:
Previously, there is no study looking at serum biomarkers for epilepsy. Epilepsy can trigger neuroinflammation events, and serum amyloid A (SAA) is one biomarker as acute-phase protein in multiple diseases. In present study, we detected serum SAA peak in epileptic patients with mass spectrometry and quantified with enzyme-linked immunosorbent assay measurement. The results suggested that in acute phase of epilepsy, the serum SAA increased, but after 3 months of treatment, the SAA peak was disappeared. In conclusion, the study provided values of proteomic diagnosis of epilepsy.
More Related Videos
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer Disease ll: Pathophysiology
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...

